BCBS Nebraska

Does BCBS Nebraska cover Mounjaro?

Quick answer · Type 2 Diabetes

BCBS Nebraska covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). A1C of 6.5% or higher
  • ACA Marketplace: Covered (preferred drug). A1C of 6.5% or higher

Last verified June 2, 2026. Policy effective November 5, 2025. Source: policy-212.html. How we verify this data →

Check your card for your exact plan →

Mounjaro for Type 2 Diabetes

What BCBS Nebraska requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Preferred GLP-1 - Prior Use within 90 Days

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Patient treated with a preferred agent within the past 90 days (samples not approvable)
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Preferred GLP-1 - New Start

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Mounjaro is a preferred GLP-1/GIP agent
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of patient age within FDA labeling OR clinical support for off-label age use
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent
  • If prior use pathway: documentation of prior preferred agent use within past 90 days (samples not acceptable)

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL per month

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent
  • Use for non-FDA approved indications (considered investigational unless excluded by contract)

Policy note: Mounjaro is a preferred agent. Step therapy through non-preferred agents is not required for preferred agents. For quantity limit exceptions: Mounjaro 2.5mg may be approved for maintenance therapy if patient has inability to use an FDA labeled maintenance strength AND has had clinical benefit at the lower strength. Policy notes metformin and insulin step therapy and comorbidity requirements were removed as of 04-01-2026 per Prime Trade agreement. Non-preferred GLP-1/GIP agents require trial/failure of TWO preferred agents (semaglutide, dulaglutide, or tirzepatide - 90 days each). Adlyxin noted in policy but is not listed as preferred or non-preferred in the formulary table.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Preferred GLP-1 - Prior Use within 90 Days

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Patient treated with a preferred agent within the past 90 days (samples not approvable)
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Preferred GLP-1 - New Start

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C >= 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Mounjaro is a preferred GLP-1/GIP agent
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5%
  • Documentation of patient age within FDA labeling OR clinical support for off-label age use
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent
  • If prior use pathway: documentation of prior preferred agent use within past 90 days (samples not acceptable)

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL per month

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent
  • Use for non-FDA approved indications (considered investigational unless excluded by contract)

Policy note: Mounjaro is a preferred agent. Step therapy through non-preferred agents is not required for preferred agents. For quantity limit exceptions: Mounjaro 2.5mg may be approved for maintenance therapy if patient has inability to use an FDA labeled maintenance strength AND has had clinical benefit at the lower strength. Policy notes metformin and insulin step therapy and comorbidity requirements were removed as of 04-01-2026 per Prime Trade agreement. Non-preferred GLP-1/GIP agents require trial/failure of TWO preferred agents (semaglutide, dulaglutide, or tirzepatide - 90 days each). Adlyxin noted in policy but is not listed as preferred or non-preferred in the formulary table.

Policy effective November 5, 2025 · verified June 2, 2026 · source: policy-212.html

Why Mounjaro requests get denied by BCBS Nebraska

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Mounjaro and Zepbound are the same molecule with different approved uses; a request for Mounjaro under a diagnosis that matches Zepbound is routinely denied.
  2. No recent A1C result on file.

Frequently asked questions

Does BCBS Nebraska cover Mounjaro?
BCBS Nebraska covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Mounjaro approval last with BCBS Nebraska?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Nebraska require to renew Mounjaro?
Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.
How current is this information?
This page reflects BCBS Nebraska's written policy as of November 5, 2025, last verified against the source document on June 2, 2026.

Other medications under BCBS Nebraska

Mounjaro coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Nebraska's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.